Key Segments:
By Vaccine Type
-
Live Attenuated Vaccines
-
Inactivated and Subunit Vaccines
-
mRNA and Viral Vector Vaccines
By Route of Administration
-
Injectable
-
Needle-Free
By Technology/Formulation
-
Lyophilized
-
Liquid
-
Microarray Patch
By Disease Indication
-
Infectious Diseases
-
Pandemic Preparedness and Emerging Infectious Diseases
-
Others
By Distribution Channel
-
Government and Institutional Procurement
-
NGO and Multilateral Procurement
-
Private and Retail Pharmacy
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Vaxart, Stablepharma, Bharat Biotech, Serum Institute of India, Sanofi, Vaxxas, Ensilicated Technologies (EnsiliTech), Micron Biomedical, Soligenix, Immunoscript Life Science, Arcturus Therapeutics, VitriVax.
The main opportunities lie in scaling needle-free delivery platforms such as oral formulations and microarray patches, and in regional manufacturers in South Asia expanding thermostable production capacity to directly supply multilateral procurement programs.
The key growth factor is reducing vaccine wastage caused by cold-chain temperature failures, reinforced by sustained multilateral funding commitment toward pandemic preparedness and outbreak response capability.
By vaccine type, the Inactivated and Subunit Vaccines segment dominated the market with approximately 38.00% share in 2025, supported by established manufacturing know-how and reliance on this platform in routine national immunization schedules.
North America dominated the market with approximately 38.00% share in 2025, supported by sustained federal biodefense procurement and a concentration of specialty biotechnology companies advancing thermostable vaccine candidates.
